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Abstract
Ovarian cancer is a leading cause of cancer mortality in women. The aim of this study was to elucidate whether whey
acidic protein (WAP) genes on chromosome 20q13.12, a region frequently amplified in this cancer, are expressed
in serous carcinoma, the most common form of the disease. Herein, we report that a trio of WAP genes (HE4, SLPI,
and Elafin) is overexpressed and secreted by serous ovarian carcinomas. To our knowledge, this is the first report
linking Elafin to ovarian cancer. Fluorescence in situ hybridization analysis of primary tumors demonstrates genomic
gains of the Elafin locus in a majority of cases. In addition, a combination of peptidomimetics, RNA interference, and
chromatin immunoprecipitation experiments shows that Elafin expression can be transcriptionally upregulated by
inflammatory cytokines through activation of the nuclear factor κB pathway. Importantly, using a clinically annotated
tissue microarray composed of late-stage, high-grade serous ovarian carcinomas, we show that Elafin expression
correlates with poor overall survival. These results, combined with our observation that Elafin is secreted by ovarian
tumors and is minimally expressed in normal tissues, suggest that Elafin may serve as a determinant of poor survival
in this disease.
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Introduction
Ovarian cancer is a major cause of cancer-related mortality in women
worldwide [1,2]. Fortuitous detection of early-stage organ-confined
disease is associated with an excellent prognosis and a 5-year survival
rate greater than 90% [3]. However, because of a lack of effective
screening methods, conditions of most patients are diagnosed at an
advanced stage when the opportunity for a surgical cure is drastically
reduced. Furthermore, whereas most patients with advanced disease
initially respond to standard chemotherapeutic regimens, the majority
ultimately relapses with chemoresistant disease [3]. Therefore, there is a
pressing need to develop new methods for early detection and prognos-
tication. CA125 is an ovarian cancer serum biomarker clinically ap-
proved for monitoring response to treatment and detection of disease
recurrence after definitive therapy [4]. However, its potential role in the
early detection of ovarian cancer is controversial, in part because ran-
domized screening trials of asymptomatic women with ovarian cancer
mortality as an end point have yet to be completed [5].
Previous studies using comparative genomic hybridization and
in silico chromosomal clustering reported that human chromosome
20q12-13.2 is consistently amplified in ovarian carcinomas and har-
bors genes that may play causal roles in the pathogenesis of the disease
[6–10]. This region contains a cluster of 14 genes with homology to
whey acidic protein (WAP) [11,12]. Among these genes is HE4 [11].
On the basis of studies from our laboratory and others showing that
HE4 is secreted by ovarian carcinomas and circulates in the blood
stream of patients with the disease [13,14], we investigated whether
other members of the WAP gene cluster are also overexpressed in this
setting. Herein, we report that a trio of WAP genes, composed ofHE4,
SLPI, and Elafin, is overexpressed and secreted by ovarian carcinomas.
Of the three, Elafin is the only one not previously reported to be asso-
ciated with ovarian cancer [13–18]. Elafin is a serine proteinase inhibi-
tor involved in inflammation and wound healing [19]. Our studies
show that Elafin overexpression is associated with poor overall survival
and is due, in part, to gains of the genomic locus and the ability to
activate the nuclear factor κB (NF-κB) pathway in ovarian cancer cells.
Materials and Methods
Cell Lines
Twenty established cell lines were used to evaluate the messenger
RNA and protein expression of the WAP genes. They included
OVCA420, OVCA429, OVCAR-3, OV-90, SKOV3, CaOV3,
OVCAR-5, OVCAR-8, IGROV1, TOV112D, TOV21G, ES2,
HEYA8, MCF7, T47D, HCT116, HCT115, U2OS, 293, and
IMR90. A majority of the lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA) and propagated in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C in
a 5% CO2-containing atmosphere. Two cell lines, OV-90 and
OVCAR-3, were propagated in 1:1 MCDB105 and Media 199
(Sigma-Aldrich, St Louis, MO) with 15% FBS, whereas CaOV3,
ES2, IGROV1, HCT116, HCT115, 293, MCF7, and IMR90 were
propagated in Dulbecco’s modification of Eagle medium (Cellgro,
Herndon, VA) with 10% FBS. Expression of the different WAP
genes, including Elafin, in these lines was compared with that of
telomerase-immortalized ovarian surface epithelial (IOSE) as previ-
ously described [13]. The term human ovarian surface epithelium
(HOSE) is used inter-changeably with IOSE.
Reverse Transcription–Polymerase Chain Reaction and
Quantitative Polymerase Chain Reaction
RNA was purified as previously described [8]. Complementary
DNA (cDNA) was synthesized from each cell line using 1 mg of
RNA, extracted from the cell lines described above, using the iScript
cDNA synthesis Kit (Bio-Rad, Hercules, CA) following the manufac-
turer’s recommendations. Epididymis cDNA was synthesized from
RNA obtained from BD Biosciences, Clontech (Palo Alto, CA). Poly-
merase chain reaction (PCR) primers are listed in Table W1. PCR
products were identified on a 2.5% Tris-acctate-EDTA agarose gel.
Quantitative amplification data were generated from 10 ng of cDNA
on Bio-Rad’s iCycler in conjunction with IQ SYBR Green (Bio-Rad,
Hercules, CA). However, when confirming Elafin expression in micro-
dissected late-stage high-grade serous tumors (n = 20) and normal OSE
(n = 10), 50 ng of amplified RNA was used.
Recombinant Protein and Antibody Production
The full-length Elafin transcript was ligated into the pGEX-2T
vector (GE Healthcare Bio-Sciences Corp, Piscataway, NJ). The modi-
fied vector was transformed into Escherichia coli Top10 (Invitrogen)
where it was amplified. The insert-containing vector was sequenced
to confirm positive selection. Induction and purification of recombi-
nant protein were done as previously described [13]. Elafin-specific
antibodies were raised by immunizing New ZealandWhite rabbits with
glutathione S -transferase (GST) fusion protein composed of full-length
Elafin and GST. Affinity-purified antibodies were generated as previ-
ously described [13]. Elafin monoclonal antibodies were purchased
from Cell Sciences (Canton, MA). Recombinant untagged Elafin was
purchased from R&D Systems (Minneapolis, MN).
Affymetrix GeneChip Amplification, Hybridization, and
Image Acquisition
Total RNA quality for each tumor and normal OSE specimen was
checked by BioAnalyzer (Agilent, Palo Alto, CA) before further ma-
nipulation. Two rounds of amplification were completed according
to the Affymetrix Two-Cycle Amplification protocol using 25 ng
of total RNA for tumor and normal OSE as previously described
[20]. A 15-μg aliquot of amplified biotinylated RNA was hybridized
to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa
Clara, CA). Arrays were scanned using the laser confocal GeneChip
Scanner 3000 (Affymetrix).
Microarray Analysis
The Robust Multichip Analysis (RMA) algorithm was applied to
the normal OSE and tumor array data. Biometric Research Branch
(BRB) ArrayTools version 3.2.2 software developed by Dr. Richard
Simon and Amy Peng Lam of the Biometrics Research Branch of
the National Cancer Institute was used to filter and complete the
statistical analysis. Only those probe sets present in greater than
50% of the arrays and displaying a variance in the top 50th percentile
were evaluated.
Differentially expressed genes were identified for tumor and OSE
specimens using a multivariate permutation t-test (P < .05). A total of
2000 permutations were completed to identify a list of probe sets
containing fewer than 5% false-positives at a confidence of 90%.
A random-variance model was selected to permit information sharing
among probe sets.
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Immunoblot Analysis
Western blots were done as previously described [13]. All blots
were developed using HRP Oxidizing and Luminol Solutions (Boston
Bioproducts, Worcester, MA) and analyzed on the FlourChem HD2
imaging system (Alpha Innotech, San Leandro, CA).
RNA Interference
Knockdown ofNF-κB activity was achieved by targeting the p65 sub-
unit with an small interfering RNA (siRNA) SMARTpool containing
four individual siRNA against p65 (Upstate/Millipore, Charlottesville,
VA). The SMARTpool sequences are 5′-GAUGAGAUCUUCCU-
ACUGU, 5′-GGAUUGAGGAGAAACGUAA, 5′-CUCAAGAU-
CUGCCGAGUGA, and 5′-GGCUAUAACUCGCCUAGUG and
are collectively labeled as siRNA p65(1). A second independent siRNA
against p65 (5′-GCUGAAGUGCAUCCAAAGGTT) was used as a
control for off-target effects (Cell Signaling, Danvers, MA) and was
labeled as siRNA p65(2). An NF-κB p65-specific antibody (sc-372;
Santa Cruz Technologies, Santa Cruz, CA) was used to analyze total
cell extracts from cells treated with the p65 SMARTpool versus control
siRNA. Equal protein loading was confirmed by immunostaining of
glyceraldehyde-3-phosphate dehydrogenase (Abcam, Cambridge, MA).
Tumor-Normal Northern Blot Analysis
Membranes loaded with RNA from matched tumor and normal
tissue samples were purchased from Clontech (Cancer Profiling Arrays I
and II; Mountain View, CA). An Elafin-specific probe was generated by
random priming of Elafin cDNA using TaKaRa Ladderman Labeling
Kit (Takara Bio, Inc, Madison, WI) according to the manufacturer’s in-
structions. Hybridization of the membranes was carried out as described
in the Cancer Profiling Array manual. The labeled membranes were
placed in a phosphor screen cassette for 14 days before it was scanned
on a Molecular Dynamics’ STORM860 system (GE Healthcare Bio-
Sciences Corp). The phosphoimage was analyzed using ImageQuant
v1.2 (Molecular Dynamics; GE Healthcare Bio-Sciences Corp).
Chromatin Immunoprecipitation
The nucleotide sequence located 1 kb upstream of the start codon of
Elafin was analyzed using a combination of algorithms that can predict
potential transcription factor binding sites (TESS http://www.cbil.
upenn.edu/cgi-bin/tess/tess and AliBaba http://darwin.nmsu.edu/
~molb470/fall2003/Projects/solorz/aliBaba_2_1.htm) and previously
published data [21,22]. We identified three potential NF-κB binding
sites. TOV21G and OVCAR8 cells were cultured to approximately
70% confluence before the medium was changed to serum-free me-
dium. Half of the plates were treated with 5 ng/ml of interleukin 1β
(IL-1β) for 2 hours. The chromatin immunoprecipitation (ChIP) assay
was done as previously described [23]. Briefly, we cross-linked cells
using formaldehyde (1%) for 10minutes at 37°C.The cells werewashed
and lysed before theywere sonicated (Misonix Sonicator 3000; Misonix,
Inc, Farmingdale, NY) three times for 10 seconds at maximum output
to shear the DNA. DNA fragment size was confirmed at 0.5 to 1.0 kb
by electrophoresis. Chromatin DNA was collected by centrifugation
and an input sample was collected and stored in −80°C. Supernatant
was diluted 1:10 in 1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl, pH 8.1 and incubated with either 1 μg of p65 anti-
body or 1 μg of anti–Golgi antibody (58K9; Abcam) and protein A
beads overnight at 4°C. The beads were then washed six times in radio-
immunoprecipitation buffer (Boston Bioproducts) and two times in
Tris-EDTA buffer before the samples were de–cross-linked in 1%
SDS, 0.1 M NaHCO3 at 65°C for 14 hours. De–cross-linked samples
were purified using Qiagen’s spin columns according to manufacturer’s
instructions (Qiagen, Valencia, CA). PCR (at 95°C for 5 minutes fol-
lowed by 35 cycles at 95°C for 30 seconds, at 60°C for 30 seconds, at
72°C for 30 seconds, followed by 72°C for 5 minutes) was performed
on (2 μg of total DNA) samples collected before IP(input) as well as
after p65-specific and control immunoprecipitation. Primers were de-
signed to span each of the putative NF-κB binding sites as well as two
control regions located 2 kb upstream and 2 kb downstream of the Ela-
fin transcription start site. Primer sequences are reported in Table W2.
Tissue Samples and Immunohistochemistry
After institutional review board approval, sections of formalin-
fixed, paraffin-embedded (FFPE) human epididymis were obtained
from the Department of Pathology at the Brigham and Women’s Hos-
pital (Boston, MA) to evaluate the expression of Elafin in this tissue and
for subsequent use as positive control tissue. Elafin expression in normal
human tissues was analyzed by immunohistochemistry (IHC) as previ-
ously described using a collection of normal human tissue blocks [13],
whereas expression in ovarian and non–ovarian tumors was analyzed
using high-density tissue microarrays (TMAs) made in-house (see below)
or purchased from Biomax US (Rockville, MD). The Elafin affinity–
purified rabbit antibody was used at a dilution of 1:1500 with heat-
induced epitope retrieval as previously described [13]. Negative controls
included protein A–purified preimmune serum, anti-GST antibodies
purified as a byproduct of Elafin antibody production, and anti-Elafin
antibodies preincubated with recombinant GST-Elafin protein before
IHC. None of these controls generated a positive signal in IHC. HE4
localization using affinity-purified antibodies was done as previously
described [13]. Slides were counterstained with Mayer hematoxylin.
Primary Tumor Cells
With institutional review board approval, primary ovarian carcinoma
cells (DF lines) were isolated directly from peritoneal paracentesis of
patients with advanced-stage ovarian cancer at the time of initial cyto-
reductive surgery. Red blood cells were lysed as previously described
[24], and the samples were enriched for tumor cells either by using im-
munomagnetic beads coupled to EpCAM antibodies (Dynal/Invitrogen)
or by filtration using a 40-μm nylon cell strainer (BD Falcon, San Jose,
CA) to isolate tumor cell spheres. Both methods enriched for tumor
cells but the yield with the cell strainer was significantly better than with
themagnetic EpCAMbeads. In all cases, the epithelial nature of the cells
was confirmed by EpCAM and HE4 antibody immunostaining as well
as reverse transcription–PCR (RT-PCR) detection of CK7. For this
study, we used only primary lines that were greater than 80% tumor
pure after enrichment.
High-Density TMA
A TMA was constructed from 134 cases of high-grade late-stage
ovarian papillary serous carcinoma who underwent primary cyto-
reductive surgery at Brigham and Women’s Hospital. Cases were iden-
tified by review of all pathology reports between January 1, 1999, and
December 31, 2005, in the Brigham and Women’s Hospital database
that included a diagnosis of “ovarian cancer.” The rationale for limiting
the enrollment date to the year 1999 is that is when taxol became the
standard of care, and the cutoff year of 2005 was established to allow
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adequate follow-up time. All cases that met the eligibility criteria of In-
ternational Federation of Gynecology and Obstetrics (FIGO) stage III
or IV high-grade papillary serous ovarian carcinoma, pathology blocks
available for generation of a TMA, and age requirements for one of two
cohorts (≤55 years or ≥65 years of age at diagnosis) were included in the
TMA (62 cases were from women ≤55 years of age, and 72 cases were
from women ≥65 years of age). Patients with known BRCA mutations
or with a history of another malignancy (excepting nonmelanoma skin
cancers or noninvasive endometrial cancers) in the previous 5 years were
excluded. Hematoxylin and eosin slides were reviewed to confirm the
original diagnosis and to identify the most appropriate area of tumor
for further studies. Corresponding FFPE tissue from each case was used
to construct four high-density TMAs: two TMAs containing samples
from the younger cohort and two TMAs containing samples from the
older cohort. Four cores of tissue were taken from each case, with each
core 0.8 mm in diameter. Five-micrometer-thick, unstained sections
of the TMAs, as well as 5-μm-thick, unstained “whole mount” sec-
tions from the formalin-fixed paraffin-embedded tissue, were used for
immunohistochemical analysis, and the findings were correlated with
clinical data (age, optimal vs suboptimal cytoreduction status, platinum
sensitivity, and overall survival) abstracted from the patient’s medical re-
cords. Optimal surgical cytoreduction was defined as residual tumor
1 cm or less in diameter, and the duration of overall survival was deter-
mined from the date of diagnosis to either death or censored by the date
of last follow-up. All pathology specimens and clinical data were col-
lected under the approval of the institutional review board.
Fluorescence In Situ Hybridization
Four-micrometer whole-mount sections of Elafin-positive high-grade
papillary serous carcinoma were mounted on standard glass slides and
baked at 60°C for at least 2 hours, then deparaffinized and digested using
methods described previously [25]. The following DNA fosmid probes
were cohybridized: G248P8772D4 and G248P82920B4 (Spectrum-
Green), which map to 20q13.12, the latter clone includes the entire
coding sequence of PI3/Elafin, and D20Z1 (SpectrumOrange), which
maps to 20p11.1-q11.1. The D20Z1 probe was purchased from Abbott
Molecular/Vysis, Inc (Des Plaines, IL). Both fosmid probes were ob-
tained from CHORI (www.chori.org), direct-labeled using nick transla-
tion and precipitated using standard protocols, and cohybridized as a
contig probe. Final (total) fosmid probe concentrationwas approximately
50 to 100 ng/μl. D20Z1 final probe concentration followed manufac-
turer’s recommendations.
Tissue sections and probes were codenatured, hybridized at least
16 hours at 37°C in a darkened humid chamber, washed in 2×
SSC at 70°C for 10 minutes, rinsed in room temperature 2× SSC,
and counterstained with 4′,6-diamidino-2-phenylindole (Abbott
Molecular/Vysis, Inc). Slides were imaged using an Olympus BX51
fluorescence microscope (Olympus, Center Valley, PA). Individual
images were captured using an Applied Imaging system running Cyto-
Vision Genus version 3.9 (Applied Imaging, Grand Rapids, MI), and
all aberrations detected by fluorescence in situ hybridization (FISH)
were reviewed and confirmed by a cytogeneticist (A.L.).
NEMO-Binding Domain (NBD) Assay
Cells were cultured until they reached 60% confluence, after which
the medium was changed to FBS-depleted. The cells were incubated
with 25 μM NEMO-Binding Domain (NBD) peptide (Calbiochem/
EMD Biosciences, San Diego, CA) or scrambled peptide (Calbiochem/
EMD Biosciences) for 24 hours before the addition of 5 ng/ml of
IL-1β. After treatment with IL-1β, the cells were cultured for an ad-
ditional 2 hours before RNA was harvested, and Elafin expression
was monitored by quantitative RT-PCR. Scrambled peptides as well
as nontreated cells were used as negative control.
Statistical Analysis
Clinical cases of late-stage ovarian serous carcinoma were scored for
Elafin expression according to the following scheme: 0 = no positive
cells, +1 = 1% to 5% positive cells, +2 = 6% to 50% positive cells
and +3 = more than 50% positive cells (Figure 4). Samples were also
scored from 1 to 3 depending on the staining intensity. All scoring was
blinded and performed by two independent pathologists (R.D. and
M.S.H.). The statistical analysis was done by a third party ( J.L.) with
no preconception of potential outcome. Before analysis of any survival
data, cases were divided into a high-Elafin expressor group (scores of +2
or +3) and a low Elafin expressor group (scores of 0 or +1). Kaplan-
Meier curves were plotted for these two groups to assess overall survival,
and the difference between the curves was evaluated using the log-rank
test. An estimate of the hazard ratio (HR) was calculated with a Cox
proportional hazards model. Statistical analysis was performed using
SAS version 9.1 software (SAS, Cary, NC).
Results
Elafin, HE4, and SLPI Constitute a Trio of Overexpressed
WAP Genes in Ovarian Cancer
A panel of six ovarian cancer cell lines was screened for expression of
WAP genes by RT-PCR. We found three WAP genes, Elafin,HE4, and
secretory leukocyte protease inhibitor (SLPI ), variably expressed in the
cancer lines. Relative to the IOSE line, HE4 and Elafin were over-
expressed only in the cancer lines. Conversely, SLPI was more broadly
expressed across all cell lines and IOSE (Figure 1A), consistent with
our previous observations [13]. Unlike HE4 and SLPI, Elafin expres-
sion has not previously been reported in ovarian cancer. We therefore
sought to investigate the expression of Elafin in primary tumors. We
used Affymetrix U133 Plus 2 chips to compare the gene expression pro-
files of microdissected late-stage high-grade ovarian serous carcinomas
(n = 66) to profiles frommicrodissected OSE (n = 10). Elafin expression
was three-fold higher in the serous late-stage carcinomas, a statistically
significant result (Figure 1B). Elafin was also significantly overexpressed
in early-stage high-grade serous carcinomas (n = 11), low-grade serous
carcinomas (n = 18), and high-grade endometrioid carcinomas (n = 18),
although there were fewer cases in these cohorts (Figure 1B). To confirm
the expression profiling results, we conducted quantitative real-time PCR
on 20 microdissected late-stage high-grade serous carcinomas and 10
microdissected OSE. Elafin transcript levels were more than 70-fold
higher in the serous carcinomas compared with microdissected OSE
(Figure 1C ). We also examined Elafin protein expression in primary
human late-stage high-grade serous tumors by IHC and found high
levels of expression compared with OSE (Figure 1D). The specificity
of the Elafin antibody was tested by Western blot analysis (Figure W1)
and IHC controls as described in the Materials andMethods. A panel of
normal benign human tissues was also examined by IHC for Elafin
expression (Table W1). Interestingly, in the epididymis, an organ de-
voted to sperm maturation and the native site of WAP gene expression
[11,26,27], expression of Elafin was restricted to the p63- and cyto-
keratin 7–positive basal cells, whereas HE4 expression was restricted to
the apical portion of luminal cells (Figure 2), suggesting that Elafin may
exhibit distinct biologic properties when compared with HE4.
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Figure 1. A trio of WAP genes is overexpressed in ovarian carcinomas. (A) Expression of the WAP genes was determined by semiquanti-
tative RT-PCR. Epididymis served as a positive control for WAP expression, and telomerase IOSE served as a cell-of-origin control. Elafin,
SLPI, and HE4 are overexpressed in a panel of ovarian carcinomas. (B) Gene expression profiling of Elafin expression in different types of
ovarian carcinomas and normal OSE. The tumors are divided into five groups: late-stage high-grade (LSHG) serous, early-stage high-grade
(ESHG) serous, low-grade (LG) serous, and LSHG endometrioid. Elafin expression is significantly higher in all tumors compared with OSE.
(C) Quantitative RT-PCR of Elafin expression in microdissected LSHG serous carcinomas (n= 20) compared with microdissected OSE (n=
10). LSHG serous cancers show a 70-fold increase of Elafin expression compared with OSE. (D) Expression of Elafin in OSE and serous
carcinoma. Representative images from a panel of 8 normal ovaries and 20 late-stage high-grade serous carcinomas immunostained for
Elafin. Original magnification, ×20.
Figure 2. Expression of Elafin in human epididymis. IHC was performed on epididymis tissue using antibodies against Elafin, HE4, p63,
and cytokeratin 7 (CK7). Elafin expression is limited to the p63- and CK7-positive basal cells, whereas HE4 is expressed in the luminal
cell compartment.
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Elafin Expression Is Restricted to Certain Tumor Types and Is
Secreted by Primary Ovarian Carcinomas
Analysis of ovarian and non–ovarian cancer cell lines by RT-PCR re-
vealed that Elafin expression is largely restricted to ovarian carcinoma
lines, including OVCAR3, OVCAR5, and CaoV3 (Figure 3A). Con-
sistent with previous reports [27], we did not observe Elafin ex-
pression in breast cancer cell lines (MCF7 and T47D). In addition,
colon (HCT115,HCT116), osteosarcoma (U2OS), kidney (293), lung
(Calu-1, NCI-H23), and brain (MO59K) cancer lines failed to express
Elafin under these conditions (Figure 3A and data not shown). Normal
diploid fibroblasts (IMR90 cells) were also negative for Elafin expres-
sion. The only non–ovarian cancer lines that expressed Elafin in this
study were the bladder tumor line T24 and the cervical cancer line
HeLa (data not shown). We also analyzed Elafin expression in tumors
by hybridizing an Elafin cDNA probe to an ATLAS cancer array mem-
brane (Clontech, Mountain View, CA), which was preloaded with
matched RNA from normal/nonneoplastic tissue and tumor tissue
derived from the same organ. Our results confirmed the higher ex-
pression of Elafin in ovarian tumors (T) versusmatched normal (N) tis-
sue (Figure 3B). The converse was true for breast normal-tumor pairs.
Interestingly, we did observe robust Elafin expression in some non–
ovarian tumors compared with the matched normal samples, includ-
ing those from the lung, vulva, and skin, all with squamous histologic
diagnosis (Figure 3B, arrowheads). Expression of Elafin by squamous
cell carcinomas was previously reported [29–32], and we confirmed it
by IHC using Elafin-specific antibodies on a TMA containing multiple
tumors, including squamous cell carcinomas from various organ sites
(Figure W2).
Elafin contains a signal peptide and is predicted to be a secreted pro-
tein [33]. Western blot analysis of conditioned medium from three
ovarian cancer lines that express Elafin RNA revealed a secreted form
of Elafin that comigrated with the recombinant protein at approxi-
mately 12 kDa (Figure 3C ). In contrast, non–ovarian cancer lines
did not secrete Elafin. We also isolated primary tumor cells directly
from ascites fluid collected from eighteen patients with advanced serous
carcinoma. Samples were enriched for tumor cells as described in the
Materials and Methods, and the presence of tumor cells was confirmed
by IHC with EpCAM and HE4 antibodies (data not shown). RT-PCR
for Elafin showed that approximately half of the primary tumor sam-
ples express Elafin, and those that did also secreted Elafin (Figure 3,
D and E ; for example compare DF-03, -04, and -20 to DF-09, -22,
and -30). As expected, the normal fibroblast line IMR90 was negative
for both Elafin and CK7 (Figure 3D).
Increased Elafin Expression in Ovarian Carcinomas Correlates
with Poor Overall Survival
Our data indicate that Elafin is overexpressed and secreted by ovarian
carcinomas. To determine whether Elafin expression is clinically signifi-
cant, we immunostained an annotated TMA composed of 134 late-
stage (FIGO stage III and IV) high-grade serous ovarian carcinomas
with our rabbit polyclonal antibody against Elafin. Two pathologists
(M.S.H. and R.D.) separately scored the sections in a blinded manner
Figure 3. Elafin is uniquely expressed by ovarian and squamous cancers. (A) RT-PCR analysis shows that Elafin is specifically expressed in
ovarian cancer cell lines (OVCAR3, OVCAR5, CaoV3), but not in other common epithelial cancer cell lines, including breast (T47D, MCF7),
kidney (293), colon (HCT-116, HCT-115), and osteosarcoma (U2OS) or in normal diploid fibroblasts (IMR90). (B) Northern dot blot analysis
for Elafin expression in matched tumor (T) and normal (N) tissue RNA. Higher Elafin expression is detected in ovarian tumor compared with
normal tissue; the converse is found in breast. Other tumors that show an increase of Elafin expression were found to be squamous cell
carcinomas (marked by black arrowheads). (C) Elafin is a secreted protein. Conditioned medium was collected from cell lines expressing
Elafin RNA as well as nonexpressors. Recombinant Elafin served as a positive control. The two bands that are observed on the Western
blot of the recombinant protein are due to a mixture of protein with or without a signal peptide. Elafin is detected in the conditionedmedium
collected from Elafin–RNA-expressing cells but not from nonexpressors. (D) Primary tumors express and secrete Elafin. Elafin expression
was determined by semiquantitative RT-PCR (27 cycles) in a collection of enriched primary tumors (DF lines). CK7 was used to validate
the epithelial nature of the tumors. Actin served as a loading control. IMR90, HOSE, OVCAR3, and epididymis served as either negative
or positive controls. (E) Primary tumors that express Elafin RNA also secreted it, as detected by Western blot analysis of conditioned me-
dium collected from primary cell lines. The first three lanes are media from nonexpressing primary tumors and the last three are from high
Elafin-expressing primary tumors. Recombinant Elafin is used as a positive control.
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according to the grading scale from 0 to 3 (Figure 4). Clinical parame-
ters included age, whether optimal cytoreduction had been achieved,
platinum sensitivity, and overall survival. Unlike HE4, which tends
to show diffuse expression in immunoreactive tumors [13], Elafin dem-
onstrated a more focal staining pattern, ranging from scattered positive
cells and clusters, to larger areas of positivity (Figure 4A). To reduce
sampling error, whole-mount sections of all the cases were also stained
for Elafin (Figure 4A). Seventy-seven cases exhibited no (score = 0) or
low (score = 1) Elafin expression (n = 33: 0, n = 44: +1) and 57 exhib-
ited high (score = 2 or 3) Elafin expression (n = 45: +2, n = 12: +3).
Importantly, there were no statistical differences in the clinical char-
acteristics of the two groups (Table 1). High Elafin expression in tumor
tissue was associated with reduced survival in patients with primary
ovarian cancer when the Cox univariate proportional hazards model
Table 1. Characteristics of High and Low Elafin Expressors.
Elafin Low (0-1) Elafin High (2-3) P *
Mean age (years) 60.4 61.7 .60
Debulking .17
Optimal 61/77 (79%) 40/57 (70%)
Suboptimal 16/77 (21%) 15/57 (26%)
Unknown 0/77 (0%) 2/57 (3.5%)
Stage .80
III 66/76 (87%) 48/57 (84%)
IV 10/76 (13%) 9/57 (16%)
Chemotherapy .56
Platinum-based 64/77 (83%) 47/57 (82%)
Nonplatinum 2/77 (2.6%) 0/57 (0%)
Unknown 11/77 (14%) 10/57 (18%)
*P value from Student’s t-test for age; Fisher’s exact test for all other variables.
Figure 4. Elafin overexpression correlates with poor overall survival. IHC on 134 serous ovarian tumors (late-stage high-grade) with an
Elafin antibody. (A) Examples of Elafin expression in ovarian tumors (10×). A few scattered positive cells (+1). Localized positive staining
(+2). Large area of cells expressing Elafin (+3) and an example at a higher magnification (40×). (B) A Kaplan-Meier curve plotting overall
survival of 77 patients with no or low Elafin expression (0 to +1, black) versus 57 high Elafin expression cases (+2 to +3, gray). Higher
Elafin expression correlates with decreased survival (P = .023, N = 134) with a median survival of 47.3 months for patients with low
Elafin expression versus 32.4 months for the patients that had tumors with higher Elafin expression. Scale used for scoring slides.
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was applied, with a HR for death of 1.65 for patients with high Elafin
expression compared with low Elafin expression (95% confidence
interval [CI], 1.07-2.54, P = .02). The relationship between Elafin
expression levels and overall survival was visualized by a Kaplan-Meier
plot (Figure 4B) and demonstrated a poorer survival in patients with high
Elafin–expressing tumors (median survival, 32.4 months; 95%CI, 24.4-
40.43 months) compared with those with no or low Elafin-expressing
tumors (median survival, 47.3 months; 95% CI, 38.6-64.2 months).
The P value for this difference was .02 by the log-rank test. Elafin re-
mained significantly correlated with overall survival in a multivariate
model incorporating age and debulking status (Table 2). Of note, al-
though Elafin expression did not correlate with platinum sensitivity or
resistance (defined as disease recurrence within 6 months of last receipt
of platinum therapy; Table 1), 10 of 11 patients with primary platinum-
refractory disease (defined as persistent disease or disease progression
while receiving platinum-based therapy) had elevated Elafin expression.
This correlation was highly statistically significant (P = 8.4 × 10−6).
Genomic Gains Drive Elafin Expression in Ovarian Cancers
The correlation between Elafin overexpression and patient outcome
prompted us to examine the nature of its overexpression. As described
previously, the Elafin gene, PI3, is located on chromosome 20q13.12,
a region frequently amplified in ovarian carcinomas [6–8]. We enter-
tained the possibility that Elafin overexpression might be due to the
amplification or gains of its genomic locus and designed DNA fosmid
probes for FISH analysis. Whole-mount sections of 10 tumors that
were scored +2 or +3 by IHC (Figure 4A) were evaluated by FISH
for aberrations involving the PI3 genomic locus (green dots). Chromo-
some 20 centromeric probes (red dots) served as controls for chromo-
somal copy number. All aberrations were verified by a cytogeneticist
(A.H.L.). Copy number changes were classified as amplified when there
was a ratio of test probe-control probe (T/C) of 3 or greater. T/C ratios
of less than 3 but greater than 1 were interpreted as relative gains of PI3.
T/C ratios of 1, even with greater than 2 copies of each probe were
classified as polysomy. Although none of the tumors analyzed revealed
amplification at the PI3 locus, half of the samples showed gains at this
locus relative to the centromeric probe (Figure 5, A and B). In addition,
trisomy was observed in three of the remaining samples (Figure 5C )
and disomy in two (Figure 5D). These data suggest that in a majority
of Elafin-expressing tumors, the underlying mechanism of overexpres-
sion may be gains of the PI3 locus and polysomy.
NF-κB Drives Expression of Elafin in Response to
Inflammatory Mediators
Although gains at the PI3 locus seem to be common in the tumors
we evaluated, it was not the case for all Elafin-expressing tumors and
it is likely that other regulatory mechanisms contribute to Elafin ex-
pression. Previous studies have demonstrated that Elafin expression is
typically induced by inflammation at the transcriptional level; the
most striking examples include psoriatic skin and inflammatory airway
Table 2. Multivariate Analysis.
HR 95% CI P
High elafin (2-3) 1.64 1.05-2.56 .03
Age 1.01 0.99-1.03 .23
Stage IV disease 1.37 0.72-2.60 .34
Optimal debulking 0.80 0.49-1.32 .39
Figure 5. Genomic gains at the PI3 locus underlie Elafin overexpression in ovarian carcinomas. FISH for the PI3 locus. The
G248P8772D4/G248P82920B4 fosmid probe (green) for PI3 was cohybridized with the control chromosome 20 centromeric probe
D20Z1 (red) on tissue sections of ten ovarian carcinomas that express high levels of Elafin protein by IHC. (A, B) Representative exam-
ples of gains of the PI3 locus compared with the control probe. (C) Example of chromosome 20 trisomy. There are three foci of both the
PI3 probe and the centromere probe. (D) Example of disomy at both the PI3 and centromeric loci.
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disease [19,34]. Given the link between chronic inflammation and
ovarian cancer pathogenesis [35–37], we examined whether inflamma-
tion might contribute to Elafin expression in ovarian cancer. A panel of
13 established ovarian cancer cell lines was screened by RT-PCR. Seven
lines were found to strongly express Elafin, whereas six demonstrated
minimal or no expression of Elafin (Figure W3). Using both computer
algorithms designed to predict transcription factor binding sites in pro-
moter regions and previously published data (reviewed in Chowdhury
et al. [22]), we identified three putative NF-κB transcription factor–
binding sites in the promoter region of Elafin (Figure 6A). We then
Figure 6. NF-κB drives the expression of Elafin in response to inflammatory mediators. (A) Schematic representation of predicted transcrip-
tion factor binding sites in the Elafin promoter. The location of these sites relative to the first base of the start codon for Elafin (+1) is in-
dicated by the number above the square. (B) A semiquantitative RT-PCR before and after IL-1β stimulation of no- or low-Elafin expressors.
Cells were treated with 5 ng/ml IL-1β for 48 hours before RNA was harvested. An increase of Elafin expression was detected in HeyA8,
OVCAR8, and TOV21G cells but not in HOSE. Actin serves as a loading control. (C) Time course of Elafin expression after cytokine treatment.
OVCAR8 cells were treated with IL-1β, and Elafin expression was monitored by quantitative RT-PCR for 48 hours. (D) Immunofluorescent
localization of p65. The NF-κB subunit p65 is normally localized in the cytoplasm of OVCAR8 cells (left panel) but is translocated into the
nucleus upon cytokine stimulation using IL-1β (middle panel). The translocation of p65 is inhibited by blocking the NF-κB pathway with a
peptide that specifically binds to the NBD, thus sequestering p65 to the cytoplasm (right panel). (E) Elafin induction by IL-1β can be abro-
gated by NBD. Scramble peptide does not inhibit the induction by IL-1β. (F) OVCAR8 cells transfected with siRNA against NF-κB subunit p65
72 hours before IL-1β treatment. Transfected cells show almost no increase in Elafin expression compared with nontransfected or cells
transfected with siRNA against GFP. Two unique siRNA give rise to similar results. Inlayed panel shows efficiency of siRNA knockdown
for p65 by Western blot; GAPDH serves as a loading control (right graph). (G) Occupancy of NF-κB sites on Elafin promoter by ChIP. In
OVCAR8 cells, NF-κB (p65) binds to the predicted binding sites 2 hours after IL-1β treatment. Anti-Golgi antibodies were used as negative
controls for the IP. Primers located 5′ and 3′ of the NF-κB sites (−2 and +2 kb, respectively) served as controls and yielded no product. Input
DNA shows that all primers give rise to products on genomic DNA. (H) IL-1β can act through NF-κB to induce further Elafin expression in
ovarian cancer lines that constitutively express Elafin. OVCAR-3 cells constitutively express Elafin compared with OVCAR-8 cell (FigureW3).
Stimulation of OVCAR-3 cells with IL-1β increases Elafin expression even further. Knockdown of NF-κB activity with siRNA against the p65
subunit (Western blot, inset) abrogates the stimulus-induced increase but not the baseline levels of Elafin expression.
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treated the ovarian cancer cells that normally express minimal or no
Elafin (Figure W3) with the cytokine IL-1β, which is known to induce
NF-κB recruitment to promoter elements of responsive genes [38].
Stimulation of HeyA8, OVCAR8, and TOV21G cells with IL-1β for
2 hours resulted in a marked expression of Elafin (Figure 6B). Tumor
necrosis factor α, another proinflammatory cytokine, had a similar al-
beit weaker effect (data not shown). Importantly, under the same
conditions, IL-1β did not induce the expression of Elafin in a HOSE
line (Figure 6B). To determine the kinetics of Elafin induction, two cell
lines, OVCAR8 and TOV21G, which normally express very low levels
of Elafin, were treated with IL-1β, and Elafin expression was monitored
over time. Two hours after IL-1β stimulation, a dramatic increase in
Elafin expression was detected: 15-fold in OVCAR8 cells (Figure 6C)
and 5-fold in TOV21G cells (data not shown). The increased expres-
sion lasted for more than 48 hours. In contrast, analysis of HE4 expres-
sion under the same conditions failed to demonstrate a similar effect
(data not shown), suggesting that Elafin and HE4 expressions are dif-
ferentially regulated. The effect of IL-1β on Elafin levels in cells that
normally do not express Elafin suggests that the NF-κB pathway
may participate in driving Elafin expression. To test this hypothesis,
we treated OVCAR8 cells with NEMO-binding domain (NBD) pep-
tide, an IκB kinase (IKKγ) inhibitor [39], 24 hours before induction
with IL-1β. IKKγ normally phosphorylates IκB and leads to its disso-
ciation from the NF-κB complex, thus permitting nuclear entry and
activation of NF-κB. Treatment of OVCAR8 cells with IL-1β results
in the nuclear translocation of NF-κB, as measured by immunofluores-
cence for the p65 DNA binding subunit of NF-κB (Figure 6D), where-
as NBD completely blocks the nuclear translocation of p65 in
the presence of IL-1β (Figure 6D). Under these conditions, cells treated
with 25 μM of the NBD inhibitor peptide before stimulation with
IL-1β showed no increase in Elafin expression, whereas the scrambled
peptide did not inhibit Elafin induction by IL-1β (Figure 6E). The ef-
fect of NBD was concentration-dependent (data not shown).
We further explored the potential direct involvement ofNF-κB in the
induction of Elafin expression using siRNA to deplete the levels of p65
before IL-1β treatment. Knockdown of p65 was confirmed byWestern
blot analysis using two different siRNA reagents (Figure 6F, inset).
OVCAR8 cells treated with control siRNA (GFP) showed comparable
levels of Elafin expression to those cells treated with IL-1β only. How-
ever, OVCAR8 cells that had been treated with siRNA against p65
showed greatly diminished induction of Elafin in response to IL-1β
(Figure 6F ). This is not likely due to an off-target effect of RNA inter-
ference (RNAi) because two different siRNA sequences gave a similar
result. Finally, ChIP was used to address whether endogenous p65
occupies its cognate DNA binding sites on the Elafin promoter after
cytokine induction, which would suggest that NF-κB directly drives
Elafin expression. In both OVCAR8 (Figure 6G ) and TOV21G cells
(data not shown), there was no occupancy of the Elafin promoter by
p65 in the absence of IL-1β. However, 2 hours after IL-1β treatment,
all three binding sites were occupied (Figure 6G). This binding is spe-
cific for three reasons: 1) it is only observed in response to a stimulus
(IL-1β), 2) control antibodies (α-Golgi) do not precipitate binding
activity, and 3) binding is specific to the NF-κB sites because binding
was not seen at sequence upstream and downstream of the NF-κB con-
sensus sites (Figure 6G ). Because the genomic resolution of ChIP is
limited by the size of DNA fragments generated (typically 500 bp after
sonication), it cannot be concluded that all three NF-κB sites are occu-
pied simultaneously because they all exist within approximately 300 bp
of one another (Figure 6A). Nonetheless, the results demonstrate that
p65 occupancy is dependent on cytokine stimulation. In addition,
the overall results strongly argue that induction of Elafin expression
by IL-1β is mediated by the NF-κB pathway in ovarian cancer cells that
normally do not express the protein. Interestingly, it should be noted
that treatment with IL-1β can also induce higher levels of Elafin expres-
sion in cell lines that constitutively express Elafin, such asOVCAR3 cells
(Figures 6H and W3). In this setting, knocking down the p65 subunit
of NF-κB resulted in a loss of the stimulus-induced expression of Elafin,
but there was no effect on the baseline level of expression (data not
shown). This latter effect is consistent with our observation that con-
stitutive expression by ovarian tumors is likely mediated by genomic
gains of the PI3 locus (Figure 5).
Discussion
In this study, we demonstrate that Elafin is overexpressed and secreted
by ovarian carcinomas. To our knowledge, this is the first report linking
Elafin to ovarian cancer. We show that Elafin expression is regulated, in
part, by gains of the genomic locus and polysomy. We also show that
inflammatory mediators can induce expression through the NF-κB
pathway, which plays a pivotal role in the link between inflammation
and cancer [40]. We could specifically block the induction of Elafin
expression with a compound (NBD peptide) that inhibits the proper
assembly of the IKK complex necessary for activation of NF-κB. RNAi
directed against the p65 DNA binding subunit of NF-κB in the pres-
ence or absence of IL-1β demonstrated that knockdown of this subunit
abrogated the induction of Elafin expression in response to this in-
flammatory mediator. Finally, using chromatin immunoprecipitation
experiments, we found that NF-κB can specifically occupy cognate
binding sites in the Elafin promoter only after stimulation with cyto-
kine. These findings are consistent with previous studies reporting a
role for NF-κB in mediating Elafin expression in pulmonary epithelial
cells in response to inflammatory mediators [34,41].
The role of Elafin in ovarian carcinoma is currently undefined. Elafin
is a serine proteinase inhibitor [19]. Its expression, and that of SLPI, is
induced under conditions of inflammation and wound healing [42].
Studies on SLPI knockout mice show impaired cutaneous wound heal-
ing with increased inflammation and elastase proteinase activity [43].
Whether Elafin plays a similar role is difficult to ascertain because there
is no direct homolog of Elafin in mouse [44]. Moreover, although SLPI
and Elafin were initially discovered because of their antiproteinase
activity, subsequent studies revealed diverse functions including anti-
microbial properties and roles in regulating the innate immune system
[19]. More recently, several studies showed that overexpression of SLPI
is common in certain tumors including pancreatic, uterine, ovarian,
and thyroid carcinomas (reviewed in Bouchard et al. [42]). One study
in particular identified SLPI among four genes associated with metas-
tasis and lymph node involvement in breast cancer [45] and another
showed that high SLPI expression is associated with decreased disease-
free survival and poor overall survival in breast cancer [46]. The func-
tion of SLPI and its antiproteinase activity in this setting are unclear.
With regard to Elafin, a connection with cancer is beginning to emerge.
A limited body of work shows that Elafin is expressed in a significant
number of squamous cell carcinomas [29–32], a finding we have con-
firmed in this study. However, it is unclear whether its expression in
these tumors is associated with clinical outcomes. A more recent study
identified Elafin expression in glioblastoma multiforme and showed a
correlation with poor outcome [47].
Our analysis of annotated TMAs and corresponding whole-mount
tissue sections of ovarian high-grade late-stage serous carcinomas shows
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that the high expression of Elafin is associated with a poorer overall
survival compared with ovarian tumors that express no or low levels
of Elafin. Whether Elafin is simply a surrogate for aggressive tumors
or it actually functionally contributes to tumor behavior by an as yet
undefined mechanism remains to be determined. However, if Elafin
secretion leads to its circulation in the bloodstream, it is tempting to
speculate that Elafin may serve as a surrogate for more aggressive, pos-
sibly more chemoresistant carcinomas that may benefit from alternative
therapies. Consistent with this hypothesis, we found that platinum-
refractory tumors in our clinical data set were very likely to have elevated
levels of Elafin expression, a finding that warrants further investigation.
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Table W1. Elafin Protein Expression in Normal Human Tissues.
Normal Tissues Positive/Tested Histologic Description
Esophagus 2/2 Mature keratinocytes
Stomach 0/3
Gallbladder 0/5
Duodenum 0/6
Colon 0/6
Pancreas Islet cells: 0/3
Glandular cells: 2/3 Weak in ductal epithelium
Liver Hepatocytes: 0/5 Weak in bile ducts
Spleen 0/2
Lymph node 0/3
Lung 0/6
Trachea Epithelium: 2/5 Weak, focal
Submucosal glands: 5/5 Moderate-to-strong
Tonsil 2/2 Squamous epithelium
Thyroid 0/6
Heart muscle 0/2
Kidney Glomeruli: 0/9
Collecting tubules: 6/9 Weak-to-moderate
Brain 0/2
Breast 7/9 Ductal epithelium
Ovary 0/8
Fallopian tubes 1/6 Focal
Endometrium 0/4
Cervix Glandular cells: 0/3
Squamous epithelium: 6/6
Epididymis 3/3 Only in basal cells
Prostate 0/6
Table W2. Primer Used for PCRs.
5′ → 3′
RT-PCR
Elafin Forward GCTCTTAGCCAAACACCTTCCTGA
Reversed GGCCTTTGACAGTGTCTTGACCTT
Forward AGGTCCAGTCTCCACTAAGC
Reversed AGCCTTCACAGCACTTCTTG
Actin Forward ACAGAGCCTCGCCTTTGC
Reversed AGGATGCCTCTCTTGCTCTG
h36b4 Forward ATCAACGGGTACAAACGAGTCCTG
Reversed AAGGCAGATGGATCAGCCAAGAAG
WFDC5 Forward GGACCAACGGAAAGAGTTCA
Reversed GACTCCCAGGAGGAGAAACC
WFDC12 Forward ACCTGGTGCTCCTCCCTAAT
Reversed TCTAGAGGCTGGGAAGTCCA
SLPI Forward AATGCCTGGATCCTGTTGAC
Reversed AAAGGACCTGGACCACACAG
WFDC2/HE4 Forward CGGCTTCACCCTAGTCTCAG
Reversed CCTCCTTATCATTGGGCAGA
EPPIN Forward ACAAGAAGTGTTGTGTCTTCAGCTGCGG
Reversed TGGCAGCCACCATAGACAAACATGGAGC
WFDC8 Forward GCTTTGGAGTGGACTTCTGC
Reversed TTCTTGAAAGGGATCCATGC
WFDC10a Forward ACAACCTGGCCAGACATAGG
Reversed TGCTTGACAATCTCGGTGAG
WFDC11 Forward CGTCGAAACCAGTGGAGATT
Reversed TGTTTGCTGTTGTCCAGCTC
WFDC13 Forward CCAGTTCCTGGTGGTGTTCT
Reversed TTGATTCTGTTGCGCTTTTG
ChIP
−2 kb Forward TCTTTAGGAGTGCAATTGCTGA
Reversed ATTTTAGATTTGAATGGGTTGTTT
+2 kb Forward GATGTGAATGAGGAGGCAAGA
Reversed GAGTGGGTCAACAGGAGAGC
NF-κB −153 Forward GGAAAACTCTTGGGACAATCA
Reversed CCTCATGGTGTCAGGAAGGT
NF-κB −331 Forward GGAGAAACACTTGGTTTTGTAA
Reversed CAGAGTAGAAGTGCTGGCTCA
NF-κB −479 Forward GAAAGGCCGTCTCTGAAACA
Reversed CAAACCCCACCCAGATCTAC
Figure W1. Elafin is secreted byovarian cancer cell lines. Conditioned
medium was harvested from cancer lines and HOSE as indicated.
Equal protein was loaded on a 4% to 12% Bis-Tris polyacrylamide
gel. After transfer, the blot was probed with affinity-purified rabbit
poly antibodies against Elafin (1:1000 dilution).
Figure W2. Expression of Elafin in Squamous Carcinomas. A multiple-organ squamous cell carcinoma TMA (BC00019; Biomax US) was
immunostained with affinity-purified antibodies against Elafin. Results are tabulated on the right.
Figure W3. Elafin expression in a panel of 13 ovarian cancer cell
lines. Elafin expression was determined by semiquantitative RT-
PCR (27 cycles). Seven of the 13 lines were found to express Elafin.
Actin served as a loading control.
